戻る
Proteomics International Laboratories Ltd (PIQLF) 収入
PIQLF 株価推移チャート
PIQLF 収入
Proteomics International Laboratories Ltd
$0.26
0%
$0
終値： Mar 24, 16:00:00 GMT-4
$0.26
0%
$0
アフターマーケット：Mar 24, 20:00:00 GMT-4
Earnings FAQ
PIQLFの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
Proteomics International Laboratories Ltd PIQLFの前四半期の収益はどうでしたか？
Proteomics International Laboratories Ltdの収益見積もりはいくらですか？
Proteomics International Laboratories Ltdの収益品質スコアはどれくらいですか？
Proteomics International Laboratories Ltdはいつ収益を報告しますか？
Proteomics International Laboratories Ltdの予想収益はいくらですか？
Proteomics International Laboratories Ltdは収益予想を上回りましたか？
主要データ
前終値
$0.26
始値
--
当日レンジ
-
52週レンジ
$0.26 - $0.31
取引高
--
平均取引高
0
配当利回り
--
1株当たり利益(TTM)
-0.04
時価総額
$42.9M
PIQLFとは何ですか？
Proteomics International Laboratories Ltd. is a medical technology company which operates at the forefront of predictive diagnostics and bio-analytical services. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2015-04-16. The firm is engaged in predictive diagnostics and bioanalytical services. The company specializes in the area of proteomics, the industrial scale study of the structure and function of proteins. The company focuses on developing and commercializing diagnostic tests for chronic diseases. Its principal activities fall into three key areas: commercialization of PromarkerD, the predictive test for diabetic kidney disease (DKD) and future kidney function decline in patients with type 2 diabetes; precision diagnostic tests in development: the Promarker pipeline, and specialist accredited analytical services on a commercial basis. Its Promarker pipeline and analytical services include PromarkerEndo, PromarkerEso and OxiDx technology. PromarkerEndo is a prototype diagnostic test for endometriosis identifying up to 90% of patients with the disease. PromarkerEso is a prototype diagnostic test for esophageal cancer.